.png)
As Co-Founder and Chief Technology Officer, I spearheaded the technical vision and regulatory roadmap for an ambitious digital health venture aimed at transforming arthritis care through computer vision. I led the end-to-end product strategy, successfully navigating the complex initial compliance frameworks required for a Class-1 medical diagnostic platform and establishing the blueprint for an innovative user experience (UX).
My role was highly cross-functional, bridging the gap between cutting-edge engineering and strategic implementation. I directed the early-stage research and development phase, managing the conceptual design of machine-learning models.
During its research phase, the Arthronica venture explored an early-stage framework for a Class-1 medical diagnostic platform. The initial R&D roadmap aimed to investigate machine-learning models that could utilize standard smartphone or laptop cameras to analyze joint range-of-motion (ROM). The theoretical goal was to determine if computer vision networks could be trained to objectively analyze data frames to assist clinical teams with automated diagnostic inputs.
My role within the venture centered on product management, regulatory compliance frameworks, implementation strategy, and user experience (UX) design.
Ultimately, due to capital constraints, the platform development was halted during the R&D stage. The proprietary networks and software architecture were never fully realised, commercialised, or finalised into protected intellectual property assets before the company was wound down and dissolved. I moved on from the project completely in 2021.
The Socioeconomic Impact of Arthritis
The human cost of chronic pain and suffering is immense, but the economic reality is equally staggering. Peer-reviewed studies analyzing healthcare data highlight the profound financial burden of these conditions:
-
$157 Billion: Spent annually on arthritis-attributable medical expenditures.
-
$326 Billion: Lost completely when combining direct medical expenditures with total earning losses.
-
1.9% of GDP: Entirely lost to arthritic pain and associated productivity drops in a single year.
Spending nearly 2% of a nation's GDP on a condition with no known cure - where treatments can only slow progression - underlines a critical systemic flaw. Effective, continuous remote tracking and early-stage diagnosis have the potential to save billions for both the US and UK healthcare economies.